AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma’s closing share price of $3.95 on October 22, 2024, and a ...

Lumos Pharma has a 52 week low of $1.37 and a 52 week high of $4.58. The firm has a market cap of $35.71 million, a PE ratio of -0.96 and a beta of 0.78.

The Merger Agreement is structured as a tender offer by a wholly owned subsidiary of DPV for 100% of the outstanding shares of common stock of Lumos Pharma for (i) $4.25 per share in cash at ...

AUSTIN, Texas - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, has agreed to be acquired by Double Point Ventures LLC (DPV) in a cash transaction valued at ...

Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHDAUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos ...

AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for ...

On Tuesday, Lumos Pharma (NASDAQ:LUMO) shares received a Buy rating from EF Hutton, with a price target set at $16.00. The new coverage is based on the firm's evaluation of the company's potential ...

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit ...

Currently, the analyst consensus on Lumos Pharma is a Moderate Buy with an average price target of $27.00, which is a 782.35% upside from current levels. In a report released today, H.C ...

investor & media contact: lisa miller lumos pharma investor relations 512-792-5454 MENAFN28062023004107003653ID1106513847 ...